NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Montefiore Medical Center
Maastricht Radiation Oncology
Instituto de Investigacion Sanitaria La Fe
IHU Strasbourg
University of Miami